Background: Minimal information is available regarding delayed adverse donor events (D-ADEs) in plateletpheresis donors. Proactive follow up of donors for D-ADEs is not done routinely by BTS. The aim of this study was to analyze frequency and type of D-ADEs and its correlation with contributory factors if any.
Methods: In this prospective observational study all eligible donors were contacted by telephone twice and asked about general wellbeing and questions specific to adverse donor events (ADEs). Donors were called at 24 hours and 2 weeks after donation. The ADEs were categorized in accordance with the International Society of Blood Transfusion standard guidelines.
Results: A total of 531 donors were analyzed in the study. D-ADEs were more common as compared to immediate ADEs (I-ADEs) (19.21% vs 5.46%, P < .0001). The most common D-ADEs were bruises (7.34%) and sore arms (3.58%). Localized D-ADEs in form of bruise and hematomas were more frequent as compared to systemic D-ADEs like fatigue and vaso-vagal reactions (16.01% vs 3.20% P < .0001). Repeat donors had a lower incidence of systemic D-ADEs (1.61% vs 6.96%, P = .001). Donors with weight ≤75 kg and platelet count ≤230 × 10 μL were more prone to systemic D-ADEs (P < .05). Citrate toxicity was more common in donors with weight ≤ 75 kg (P = .002).
Conclusions: Plateletpheresis procedures are relatively safer without any sequelae. D-ADEs are more common than I-ADEs. Localized D-ADEs are more frequent than systemic D-ADEs. First-time donors are more prone to D-ADEs than repeat donors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jca.21753 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies.
Eur Respir J
January 2025
Université Paris-Saclay, INSERM Unité Mixte de Recherche en Santé 999 (HPPIT), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), Le Kremlin-Bicêtre, France.
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the growth-promoting and growth-inhibiting signalling pathways.
Methods: This post-hoc, exploratory, pooled analysis combines data from the double-blind placebo periods of the phase 2 PULSAR (NCT03496207) and phase 3 STELLAR (NCT04576988) studies.
Exploring the Influence of PCBs Exposure on Neonatal Birth Outcomes and Neurobehavioral Development after 20 years of prohibition.
Environ Pollut
January 2025
Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taiwan. Electronic address:
Despite polychlorinated biphenyls (PCBs) have been banned in Taiwan for two decades, epidemiological studies indicated that prenatal PCBs exposure may still affect newborns and their birth outcomes. The study aimed to investigate the association between PCB concentrations in umbilical cord blood and infants' birth outcomes and neurodevelopment. We recruited 100 pairs of mothers and infants, residing in Changhua and Yunlin countries in Taiwan from 2014-2016.
View Article and Find Full Text PDFChimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel.
View Article and Find Full Text PDFLong-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Neurology
February 2025
Department of Neurology and Center of Clinical Neuroscience, First Medical Faculty, General University Hospital and Charles University, Prague, Czech Republic.
Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).
Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.
Increased expression of the small lysosomal gene SVIP in the Drosophila gut suppresses pathophysiological features associated with a high-fat diet.
Biol Open
February 2025
Louisiana State University, Department of Biological Sciences, Baton Rouge, LA 70803, USA.
Lysosomes are digestive organelles that are crucial for nutrient sensing and metabolism. Lysosome impairment is linked to a broad spectrum of metabolic disorders, underscoring their importance to human health. Thus, lysosomes are an attractive target for metabolic disease therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!